Your browser doesn't support javascript.
loading
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler, Annika; Au, Lewis; Shepherd, Scott T C; Byrne, Fiona; Cerrone, Maddalena; Boos, Laura Amanda; Rzeniewicz, Karolina; Gordon, William; Shum, Ben; Gerard, Camille L; Ward, Barry; Xie, Wenyi; Schmitt, Andreas M; Joharatnam-Hogan, Nalinie; Cornish, Georgina H; Pule, Martin; Mekkaoui, Leila; Ng, Kevin W; Carlyle, Eleanor; Edmonds, Kim; Del Rosario, Lyra; Sarker, Sarah; Lingard, Karla; Mangwende, Mary; Holt, Lucy; Ahmod, Hamid; Stone, Richard; Gomes, Camila; Flynn, Helen R; Agua-Doce, Ana; Hobson, Philip; Caidan, Simon; Howell, Michael; Wu, Mary; Goldstone, Robert; Crawford, Margaret; Cubitt, Laura; Patel, Harshil; Gavrielides, Mike; Nye, Emma; Snijders, Ambrosius P; MacRae, James I; Nicod, Jerome; Gronthoud, Firza; Shea, Robyn L; Messiou, Christina; Cunningham, David; Chau, Ian; Starling, Naureen; Turner, Nicholas.
Afiliação
  • Fendler A; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Au L; Equal contribution.
  • Shepherd STC; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Byrne F; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Cerrone M; Equal contribution.
  • Boos LA; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Rzeniewicz K; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Gordon W; Equal contribution.
  • Shum B; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Gerard CL; Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Ward B; Department of Infectious Disease, Imperial College London, W12 0NN, UK.
  • Xie W; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Schmitt AM; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Joharatnam-Hogan N; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Cornish GH; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Pule M; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Mekkaoui L; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Ng KW; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Carlyle E; Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Edmonds K; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Del Rosario L; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Sarker S; Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Lingard K; Research Department of Haematology at University College London Cancer Institute, WC1E 6DD, London, UK.
  • Mangwende M; Autolus Limited, The MediaWorks, 191 Wood Lane, London, W12 7F.
  • Holt L; Autolus Limited, The MediaWorks, 191 Wood Lane, London, W12 7F.
  • Ahmod H; Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Stone R; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Gomes C; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Flynn HR; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Agua-Doce A; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Hobson P; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Caidan S; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Howell M; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Wu M; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
  • Goldstone R; Autolus Limited, The MediaWorks, 191 Wood Lane, London, W12 7F.
  • Crawford M; Autolus Limited, The MediaWorks, 191 Wood Lane, London, W12 7F.
  • Cubitt L; Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
  • Patel H; Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
  • Gavrielides M; Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
  • Nye E; Safety, Health & Sustainability, The Francis Crick Institute, London, NW1 1AT, UK.
  • Snijders AP; High Throughput Screening Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • MacRae JI; High Throughput Screening Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Nicod J; Advanced Sequencing Facility, The Francis Crick Institute, London, NW1 1AT, UK.
  • Gronthoud F; Advanced Sequencing Facility, The Francis Crick Institute, London, NW1 1AT, UK.
  • Shea RL; Advanced Sequencing Facility, The Francis Crick Institute, London, NW1 1AT, UK.
  • Messiou C; Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
  • Cunningham D; Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
  • Chau I; Experimental Histopathology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
  • Starling N; Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
  • Turner N; Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK.
Res Sq ; 2021 Sep 20.
Article em En | MEDLINE | ID: mdl-34580668
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2-positive, 94 were symptomatic and 2 patients died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies, 82% had neutralizing antibodies against WT, whereas neutralizing antibody titers (NAbT) against the Alpha, Beta, and Delta variants were substantially reduced. Whereas S1-reactive antibody levels decreased in 13% of patients, NAbT remained stable up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment-specific, but presented compensatory cellular responses, further supported by clinical. Overall, these findings advance the understanding of the nature and duration of immune response to SARS-CoV-2 in patients with cancer.
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Res Sq Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Res Sq Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos